Cargando…
Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy
Background: Information on immune responses in cancer patients following mRNA COVID-19 vaccines is still insufficient, but generally, patients had impaired serological responses, especially those with hematological malignancies. We evaluated serological response to COVID-19 mRNA vaccine in cancer pa...
Autores principales: | Mencoboni, Manlio, Fontana, Vincenzo, Damiani, Azzurra, Spitaleri, Antonino, Raso, Alessandro, Bottaro, Luigi Carlo, Rossi, Giovanni, Canobbio, Luciano, La Camera, Antonella, Filiberti, Rosa Angela, Taveggia, Paola, Cavo, Alessia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139308/ https://www.ncbi.nlm.nih.gov/pubmed/35621663 http://dx.doi.org/10.3390/curroncol29050273 |
Ejemplares similares
-
Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis
por: Mencoboni, Manlio, et al.
Publicado: (2021) -
Contemporary Hematology/Oncology
por: Geary, C. G.
Publicado: (1980) -
Harrison’s Hematology and Oncology
por: Dray, Nicolas
Publicado: (2011) -
Hematological and Oncological Emergencies
por: Bertz, Hartmut, et al.
Publicado: (2008) -
Nanopharmacology in translational hematology and oncology
por: Tomuleasa, Ciprian, et al.
Publicado: (2014)